Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - pioglitazone hydrochloride, quantity: 16.536 mg (equivalent: pioglitazone, qty 15 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes inadequately controlled by diet and exercise: ? as monotherapy ? as dual therapy to improve glycaemic control - in combination with metformin or sulfonylurea - in combination with insulin ? as triple therapy to improve glycaemic control - in combination with metformin and sulfonylurea

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - pioglitazone hydrochloride, quantity: 16.536 mg (equivalent: pioglitazone, qty 15 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes inadequately controlled by diet and exercise: ? as monotherapy ? as dual therapy to improve glycaemic control - in combination with metformin or sulfonylurea - in combination with insulin ? as triple therapy to improve glycaemic control - in combination with metformin and sulfonylurea

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - pioglitazone hydrochloride, quantity: 16.536 mg (equivalent: pioglitazone, qty 15 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes inadequately controlled by diet and exercise: ? as monotherapy ? as dual therapy to improve glycaemic control - in combination with metformin or sulfonylurea - in combination with insulin ? as triple therapy to improve glycaemic control - in combination with metformin and sulfonylurea

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - pioglitazone hydrochloride, quantity: 16.536 mg (equivalent: pioglitazone, qty 15 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes inadequately controlled by diet and exercise: ? as monotherapy ? as dual therapy to improve glycaemic control - in combination with metformin or sulfonylurea - in combination with insulin ? as triple therapy to improve glycaemic control - in combination with metformin and sulfonylurea

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - pioglitazone hydrochloride, quantity: 16.536 mg (equivalent: pioglitazone, qty 15 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes inadequately controlled by diet and exercise: ? as monotherapy ? as dual therapy to improve glycaemic control - in combination with metformin or sulfonylurea - in combination with insulin ? as triple therapy to improve glycaemic control - in combination with metformin and sulfonylurea

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - pioglitazone hydrochloride, quantity: 16.536 mg (equivalent: pioglitazone, qty 15 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes inadequately controlled by diet and exercise: ? as monotherapy ? as dual therapy to improve glycaemic control - in combination with metformin or sulfonylurea - in combination with insulin ? as triple therapy to improve glycaemic control - in combination with metformin and sulfonylurea

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - pioglitazone hydrochloride, quantity: 16.536 mg (equivalent: pioglitazone, qty 15 mg) - tablet - excipient ingredients: lactose monohydrate; carmellose calcium; hyprolose; magnesium stearate - treatment of type 2 diabetes inadequately controlled by diet and exercise: ? as monotherapy ? as dual therapy to improve glycaemic control - in combination with metformin or sulfonylurea - in combination with insulin ? as triple therapy to improve glycaemic control - in combination with metformin and sulfonylurea

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pioglitazone hydrochloride, quantity: 16.536 mg (equivalent: pioglitazone, qty 15 mg) - tablet - excipient ingredients: carmellose calcium; hyprolose; magnesium stearate; lactose monohydrate - treatment of type 2 diabetes inadequately controlled by diet and exercise: ? as monotherapy ? as dual therapy to improve glycaemic control - in combination with metformin or sulfonylurea - in combination with insulin ? as triple therapy to improve glycaemic control - in combination with metformin and sulfonylurea

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pioglitazone hydrochloride, quantity: 16.536 mg (equivalent: pioglitazone, qty 15 mg) - tablet - excipient ingredients: magnesium stearate; carmellose calcium; hyprolose; lactose monohydrate - treatment of type 2 diabetes inadequately controlled by diet and exercise: ? as monotherapy ? as dual therapy to improve glycaemic control - in combination with metformin or sulfonylurea - in combination with insulin ? as triple therapy to improve glycaemic control - in combination with metformin and sulfonylurea

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - pioglitazone 15 mg - pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and metformin is appropriate [see clinical studies (14)] . important limitations of use pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. pioglitazone and metformin hydrochloride tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. use caution in patients with liver disease [see warnings and precautions (5.5)] . limited data with pioglitazone and metformin hydrochloride tablets or pioglitazone in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [see data]. there are risks to the mother a